Open AccessCiclosporin Therapy After Infliximab Failure in Hospitalized Patients With Acute Severe Colitis is Effective and Safe
Author(s) -
Roni Weisshof,
Jacob Ollech,
Katia El Jurdi,
Olivia V. Yvellez,
Russell D. Cohen,
Atsushi Sakuraba,
Sushila Dalal,
Joel Pekow,
David T. Rubin
Publication year - 2019
Publication title -
journal of crohn's and colitis
Language(s) - English
Resource type - Journals
eISSN - 1876-4479
pISSN - 1873-9946
DOI - 10.1093/ecco-jcc/jjz032
Subject(s) - medicine , infliximab , ciclosporin , adverse effect , rescue therapy , discontinuation , interquartile range , colectomy , refractory (planetary science) , surgery , colitis , retrospective cohort study , immunosuppression , ulcerative colitis , chemotherapy , physics , disease , astrobiology
Options for medical management of patients with acute severe colitis [ASC] failing intravenous (i.v.) steroids are limited and include rescue therapy with either infliximab or ciclosporin. In patients failing infliximab, second-line rescue therapy with ciclosporin is an alternative. The aim of this study was to investigate the efficacy and safety of ciclosporin in patients with steroid-refractory ASC failing first-line rescue therapy with infliximab.